Drug Profile
BBI 21007
Alternative Names: BBI-21007Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Biousian Biosystems
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Diabetic neuropathies in USA (unspecified route) (Biousian Biosystems pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Diabetic-neuropathies in USA
- 22 Jul 2016 Preclinical trials in Diabetic neuropathies in USA (unspecified route)